Analyst Upgrade Boosts Dr. Reddy's Stock View

Prabhudas Lilladher has upgraded Dr. Reddy's Laboratories (DRRD) to 'Accumulate' from 'Reduce', setting a new price target of INR 1400 per share. This target is based on a 23x multiple of projected FY28 earnings, suggesting confidence in the company's growth. The brokerage slightly lowered its FY27 and FY28 earnings per share estimates by 3-6%.

Margin Recovery Fueled by New Drug Launches

Dr. Reddy's Laboratories reported Q4FY26 results that included one-time items, such as a shelf stock adjustment for gRevlimid. Excluding these, the base business generated EBITDA of INR 12 billion, with an operating margin of about 15%. Analysts see a strong potential for margin recovery, driven by the successful launch of Semaglutide in major markets and better control of overhead costs. The introduction of products like bAbatacept, expected later, could boost profitability from the second half of fiscal year 2028. The company also maintains strong performance in its domestic and Russian markets.

Pipeline Investment and Valuation

Prabhudas Lilladher expects Dr. Reddy's base business margins to grow from 15-16% to about 21% by FY28. This growth is expected from reinvesting cash generated from gRevlimid into developing peptides, biosimilars, and GLP-1 drugs, with initial commercial benefits anticipated from fiscal year 2027. Currently, Dr. Reddy's trades at 21 times its estimated FY28 earnings per share. This compares to competitors like Sun Pharma at roughly 22x, Cipla around 20x, and Zydus Lifesciences at 28x. The Indian pharmaceutical sector has seen moderate growth recently, with companies focusing on specialty generics and biosimilars amid pressures from R&D costs and market competition. Historically, positive analyst views have led to short-term stock gains for Dr. Reddy's, but lasting increases depend on pipeline progress and strong execution.

Execution Risks and Concerns

A key concern for investors is the risk of slower-than-expected scaling for Semaglutide, a highly competitive drug requiring strong market penetration and patient access. Long development cycles and high R&D costs for complex drugs like peptides and biosimilars also carry risks of delays or failure, which the current stock valuation may not fully reflect. Unlike peers with more established products or lower debt, Dr. Reddy's pipeline investment requires capital that may not yield returns for years, potentially affecting near-term cash flow. Additionally, unforeseen regulatory issues or pricing pressure in key markets, especially the US, could hinder margin recovery targets. Management's ability to successfully navigate these complex launches will be closely watched.

Looking Ahead

Benefits from Dr. Reddy's pipeline investments, particularly in advanced therapies, are expected to become clearer from fiscal year 2027. The company's strategy to reinvest cash into growth shows a long-term vision. However, achieving the target operating margins of 21% by FY28 depends on successfully launching multiple complex products and maintaining strength in its domestic and international markets.